Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL28548246 | 0.88 | L3MBTL1 (0.61) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL8930633 | 0.88 | L3MBTL1 (0.67) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL2512343 | 0.86 | L3MBTL1 (0.65) | L3MBTL1TSHRHTTMAPTLMNA | |
| Ethylene SCHEMBL27874359 | 0.85 | L3MBTL1 (0.64) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL12227212 | 0.85 | L3MBTL1 (0.64) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL28914785 | 0.85 | L3MBTL1 (0.64) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL12227200 | 0.85 | L3MBTL1 (0.64) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL12227206 | 0.85 | MAPT (0.66) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL30080354 | 0.85 | L3MBTL1 (0.64) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL13009640 | 0.84 | L3MBTL1 (0.62) | L3MBTL1TSHRHTTMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020112605-A1 | COMPOUNDS AND METHODS FOR TREATING CHRONIC MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | L3MBTL1 3309/4885TSHR 271/4885HTT 583/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | L3MBTL1 3949/4885TSHR 156/4885HTT 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.